Intermittent Preventive Treatment for Malaria

Intermittent Preventive Treatment for Malaria is a World Health Organization-endorsed public health strategy that gives full therapeutic courses of antimalarial medicine, most often sulfadoxine-pyrimethamine, to people at high risk on a scheduled basis regardless of whether they show signs of infection, in order to clear existing parasites and prevent new malaria episodes. It exists in several forms targeted at different groups, including pregnant women (IPTp), infants (IPTi), children (IPTc), and schoolchildren (IPTsc), and it was first tested in Ifakara, Tanzania in 1999, where an early trial found roughly fifty nine percent efficacy against clinical malaria attacks in infants. The World Health Organization recommended the approach in March 2010, specifically endorsing the co-administration of sulfadoxine-pyrimethamine with routine childhood vaccinations in sub-Saharan African regions with high malaria transmission and low drug resistance, and the Bill and Melinda Gates Foundation invested roughly twenty eight million dollars in the IPTi Consortium to support its rollout. National malaria programs across sub-Saharan Africa have adopted versions of the strategy, though its real-world effectiveness has proven more contested than the original trial results, with later studies finding protective rates of only twenty to thirty three percent in some settings.